Determination of clofarabine triphosphate concentrations in leukemia cells using sensitive, isocratic high-performance liquid chromatography

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2863-2867

  Yamauchi, Takahiro ^a   Nishi, Rie ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Cl F ara A; Cl F ara ATP; Clofarabine; Clofarabine triphosphate; Isocratic HPLC; Leukemia cells

Indexed keywords

ACETONITRILE; ADENOSINE TRIPHOSPHATE; CLOFARABINE; CLOFARABINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE; GUANOSINE TRIPHOSPHATE; PHOSPHATE; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ANION EXCHANGE; ARTICLE; CONCENTRATION RESPONSE; ENVIRONMENTAL TEMPERATURE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HL-60 CELLS; HUMANS; LEUKEMIA; REPRODUCIBILITY OF RESULTS;

EID: 80051605009     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Zhenchuk A, Lotfi K, Juliusson G and Albertioni F: Mechanisms of anticancer action and pharmacology of clofarabine. Biochem Pharmacol 78: 1351-1359, 2009.
2. Cooper T, Kantarjian H, Plunkett W and Gandhi V: Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids 23: 1417-1423, 2004. (Pubitemid 39625936)
3. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W and Kantarjian HM: The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 103: 1985-1995, 2005.
4. Gandhi V and Plunkett W: Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 18: 584-590, 2006. (Pubitemid 44427632)
5. Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist JA 3rd and Bennett LL Jr: Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51: 2386-2394, 1991.
6. Xie C and Plunkett W: Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluorobeta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55: 2847-2852, 1995.
7. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO and Keating MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12(2 Suppl 3): 20-30, 1985. (Pubitemid 15063578)
8. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E and Keating MJ: Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20(5 Suppl 7): 2-12, 1993. (Pubitemid 23333771)
9. Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M and Ueda T: Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. Cancer Sci (Jpn J Cancer Res) 92: 546-553, 2001. (Pubitemid 32515096)
10. Yamauchi T, Kawai Y, Goto N, Kishi S, Imamura S, Yoshida A, Urasaki Y, Fukushima T, Iwasaki H, Tsutani H, Masada M and Ueda T: Close correlation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N4-behenoyl-1-β-D- arabinofuranosylcytosine therapy for acute myelogenous leukemia. Cancer Sci (Jpn J Cancer Res) 92: 975-982, 2001. (Pubitemid 32970439)
11. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W and Freireich EJ: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102: 2379-2386, 2003. (Pubitemid 37193573)
12. Rodriguez CO Jr, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ and Gandhi V: A high-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatography B Biomed Sci Appl 745: 421-430, 2000. (Pubitemid 30665566)
13. Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S and Keating MJ: Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 12: 4011-4017, 2006. (Pubitemid 44078088)
14. Yamauchi T and Ueda T: Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic high-performance liquid chromatography. J Chromatography B Biomed Sci Appl 799: 81-86, 2004. (Pubitemid 37500865)
15. Yamauchi T, Ueda T and Nakamura T. A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. Cancer Res 56: 1800-1804, 1996.
16. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ and Plunkett W: Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9: 6335-6342, 2003. (Pubitemid 38031817)
17. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V and Plunkett W: Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 28: 2755-2760, 2010.
18. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ and Appelbaum FR: Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 151: 430-434, 2010.